This post has been archived and contains information that may be out of date.
Over the past several weeks, the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) has made several changes and updates to the distribution and allocation of currently available treatments for COVID-19, including monoclonal antibodies and oral antivirals.
The ongoing changes to distribution are necessary to address the increasing prevalence of the omicron variant and to include new therapeutics as they become available. Overall, the supply of both monoclonal antibodies and oral antivirals remains limited.
Allocation and distribution continue to be managed on a statewide basis by the California Department of Public Health in coordination with local health departments. Medical providers with questions about availability or interested in receiving additional supply should contact their Medical Health Operational Area Coordinator.
HHS ASPR has also developed a COVID-19 therapeutics decision aid and guidelines for prioritization of treatment, particularly when supplies are limited. Additional information is available on the HHS ASPR website.